Cancer and Immunotherapy Vaccine Conference 2017 logo

From new adjuvant technologies to novel immunotherapies, better understand the latest developments in the fast-evolving cancer landscape

ABOUT THE
CANCER AND IMMUNOTHERAPY VACCINE CONFERENCE

 

With so much activity around cancer vaccines and immunotherapy right now, can you afford to miss out?

It is the place where the global market will come together to share the latest in earlystage scientific advancements, present clinical trial data, discuss new formulations of cancer vaccines and assess the future of combination treatments.

Make sure that people are aware of the work you are doing to put yourself at the forefront of the industry.

SCROLL DOWN FOR THE 2017 AGENDA 

 

 

2017 AGENDA

Cancer & Immunotherapy, Tuesday 11 April 2017

Professor Bruce Levine
Cancer & Immunotherapy
09:10

Using CAR T-cells to target hematologic malignancies and in solid tumors to demonstrate the possibility to design immunity at will for therapeutic application

  • Progress of chimeric antigen receptor (CAR) T-cells targeting CD19 on B-cells leukemias and lymphomas
  • Inducing durable complete responses in patients who are relapsed or refractory to all other available treatments 
  • Targeting new targets in hematologic malignancies and in solid tumors
Dr Lelia Delamarre
Cancer & Immunotherapy
09:40

Personalized cancer vaccines that target patients-specific mutations – a reality?

  • Neoantigen identification
  • Platforms amenable for neoantigen vaccination
  • Review of the recent clinical trial data  in the field of neoantigen vaccines
Dr Michael Kalos
Cancer & Immunotherapy
10:10

The renaissance of cancer vaccines: Biomarker strategies for T-cell vaccines

10:40

Networking coffee break

Dr David Kaufman
Cancer & Immunotherapy
11:40

Use of biomarkers and immunotherapy in cancer and combinational studies

  • The rationale of combining biomarkers and checkpoint inhibitors with vaccines and oncolytics
Professor Ugur Sahin
Cancer & Immunotherapy
12:10

Using RNA based vaccines as delivery method to dendritic cells exploits antiviral defence for cancer immunotherapy

  • Overcoming the technical challenges that hinder delivery of vaccine antigens into dendritic cells (DCs)
  • How DCs can be targeted precisely and effectively in vivo using intravenously administration
Dr Douglas Mcneel
Cancer & Immunotherapy
12:40

DNA vaccines as cancer therapeutics

  • Selection of Appropriate Vaccine Antigens for Prostate Cancer
  • Synergy of DNA Vaccines with Checkpoint Inhibitors
  • Three Ongoing Translational Trials of DNA Vaccines in Prostate Cancer
13:10

Networking Lunch & Poster Session

Dr Niranjan Sardesai
Cancer & Immunotherapy
14:40

Clinical and immunological predictors for lesion regression and viral clearance following HPV immunotherapy

  • Identification of immunological signatures that predict treatment outcomes with VGX-3100 therapy
  • Implications for cancer immunotherapy with tumor targeted antigens
  • Advancing combinatorial approaches with cancer vaccines that drive antigen specific CD8 T-cells
Dr Steven Swanson
Cancer & Immunotherapy
15:10

Novel personalized immune therapies for solid tumors

  • Rationale for use of immunotherapy in glioblastoma
  • Mobilizing the immune system through patient specific biomarkers, obtained from their tumor
  • Providing a clinical update on the vaccine progress in patients
  • Strategy for design of a Ph III trial immunotherapy trial incorporating lessons learned during Ph II
  • Challenges with manufacturing personalized immunotherapy
Dr David E. Anderson
Cancer & Immunotherapy
15:40

VBI-1901: Harnessing Foreign Viral CMV Antigens to Re-Stimulate Anti-Tumor Immunity

  •  
16:10

Networking coffee break

Dr Howard Kaufman
Cancer & Immunotherapy
16:40

Oncolytic virus T-VEC shows therapeutic benefit against melanoma after randomized PhIII study

  • Designing a clinical trial for a new class of drugs – what to test and look for
  • Establishing the legitimacy of oncolytic viruses in cancer therapy, allowing more research in other types of viruses and in approaches where other viral vectors can be combined
  • Taking it outside of melanoma and theoretically to any cancer
Mr Lars Staal Wegner
Cancer & Immunotherapy
17:10

MVA, viral vector, past, present and future in immune-oncology

  • Combining our cancer vaccines with checkpoint inhibitors
  • Progress on the new PhII and PhIII trials results
Cancer & Immunotherapy
17:40

For vaccines that are being paired with adjuvant or checkpoint blockade therapies, are we working with the right antigenic targets?

  • What technologies will enable a quick turnaround time for producing personalized vaccine formulations? What delivery systems are supported by the FDA?
  • How will combinational approaches reduce side effects and replace conventional treatments including chemotherapy?
  • Are we leveraging the power of biomarkers that pinpoint which patient subpopulations that would be the ideal candidates for a given immunotherapeutic regimen
  • Using patient’s genetic makeup to design and execute an optimal therapeutic strategy
  • Does the future involve companion diagnostics?
18:40

Chair’s closing remarks and close of congress day 2

18:45

Networking Drinks & Party

last published: 12/Jan/17 13:36

 

Cancer & Immunotherapy, Wednesday 12 April 2017

Dr Bernard Fox
Cancer & Immunotherapy
09:10

How to overcome tumour immunosuppression – Understanding immunosuppression in the microenvironment that leads to anti-tumour activity

  • Understanding the mechanism that is preventing T-cells from killing cancer cells
  • The important role tumor-induced T reg cells play and development of strategies to overcome this effect
  • Employing anti-CD4 antibody to partially deplete CD4 T-cells
  • Using this method in PhI clinical trials to uncover therapeutic efficacy in a multiple vaccination model
Dr Jay A. Berzofsky
Cancer & Immunotherapy
09:40

Translating cancer vaccines from mice to human clinical trials

Professor Laure Aurelian
Cancer & Immunotherapy
10:10

Can understanding antiviral immunity induced by oncolytic viruses predict their success as a tumor immunotherapy?

  • Oncolytic viruses as immunotherapy: progress and remaining challenges
  • How do we restrain antiviral immune responses and minimize pathology while promoting antitumor immunity to override immune tolerance?
  • Combining OV therapy with chemo- and immune-based therapeutic regimens and the risks
10:40

Networking coffee break

Mr Keith L Knutson
Cancer & Immunotherapy
11:30

Self-antigen T-cell vaccines for the treatment and prevention of breast and ovarian cancers

 
  • Integrating different cancer vaccine types and check point inhibitors in combinational approaches
  • Augmenting CD4 helper T-cell immunity using peptide epitopes
Dr Jessica Baker Flechtner
Cancer & Immunotherapy
12:00

Comprehensive profiling of T cell responses to putative neoantigens reveals smarter targets for cancer immunotherapy

  • ATLAS™ is a clinically-proven platform that can comprehensively characterize the specificity and quality of HLA-diverse human T cell responses
  • T cell neoantigens identified using ATLAS are often missed by algorithms
  • Inhibitory neoantigens are emerging that could not be predicted in silico
  • ATLAS T cell profiles predict response to checkpoint blockade therapy
12:30

Networking Lunch & Poster Session

Dr Alan R. Hinman
13:40

The eradication of Polio: Have we succeeded?


-    Measuring and monitoring the success of eradication
-    End game and strategic plan
-    What’s next? Can we eradicate measles?
 
Professor Robert Daum
14:10

A call for greater consideration for the role of vaccines in national strategies to combat antibiotic-resistant bacteria


-    Recommendations from the National Vaccine Advisory Committee
-    Use of vaccines to prevent the infections that could or have developed AMR to antibiotics, in adjunction to antibiotic stewardship
-    Examples in Haemophilus influenza, Streptococcus, Staphylococcus aureus

 
Dr Danilo Casimiro
14:40

Panel: How much efficacy is enough? What are the implications of a vaccine no longer being a replacement technology but a companion technology?


-    The concept of partially protected vaccines like malaria, TB, NTDs where the clinical efficacy is no longer 85/90% but closer to 40% 
-    Future of vaccine development 
-    The combining drivers of technology and emerging diseases

More panelists to be announced shortly
15:30

Chair’s closing remarks and close of congress

last published: 12/Jan/17 13:37

 

Sign up for event updates

WHO ATTENDS?

  • Pharma
  • Biotech
  • National and International Government
  • Non-Profit Organizations
  • Academics And Research Institutions ​

JOB TITLES

  • CEO / CSO / COO
  • CMO / Head of Scientific Affairs
  • Head of Oncology
  • Head of Immuno-Oncology
  • Head of R&D ​

 

 

WHO SPONSORS?

This is a prime opportunity for specialists in oncology from:

  • Platform Technology Providers
  • Biotechs
  • Big Pharma